Web Analytics

3 Latest Announced Rounds

  • $10,500,000
    Unknown

    3 Investors

    HVAC and Refrigeration Equipment Manufacturing
    Nov 5th, 2024
  • $4,000,000
    Series A
    Financial Services
    Nov 5th, 2024
  • $1,000,000
    Pre-Seed

    1 Investors

    Data Infrastructure and Analytics
    Nov 5th, 2024
$1,349.98M Raised in 67 Funding Rounds in the past 7 Days - View All

Funding Round Profile

CND Life Sciences

start up
United States - Scottsdale, Arizona
  • 07/04/2023
  • Seed
  • $4,500,000

CND Life Sciences is dedicated to supporting the care of patients suffering from neurodegenerative diseases and other conditions. Operating a CLIA-certified laboratory in Scottsdale, AZ, CND launched the Syn-One Test® as the first commercially available test to detect, visualize, and quantify the presence of misfolded phosphorylated alpha-synuclein in cutaneous nerve fibers. The test serves as an objective diagnostic tool to aid in the confirmation of a synucleinopathy in patients with suspected Parkinson’s disease (PD), dementia with Lewy bodies (DLB), multiple system atrophy (MSA), or pure autonomic failure (PAF). Through analysis of three small in-office skin biopsies provided by a referring physician, CND offers a convenient, accurate, minimally invasive alternative to aid in the diagnosis of neurodegenerative diseases. The company has research collaborations with multiple biopharmaceutical companies and is committed to advancing science in the field.


Related People

Rick MorelloFounder

Rick Morello United States - Atlanta, Georgia

N/A